"versionIdentifier","instanceType","uuid:ID","rationale","id"
"2","StudyVersion","2e98d469-3502-4c88-842e-008182407bdc","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1"
